Dr. Amit Khanna – iPSC – Stem cells- Best Researcher Award

Dr. Amit Khanna - iPSC - Stem cells - Best Researcher Award

Yashraj Biotechnology - India 

Author Profile 

ORCID 

🎓 Early academic pursuits

Dr. Amit Khanna's journey into the scientific world began with a strong foundation in bioinformatics and life sciences, complemented by a master's degree in technology (m.tech) and a doctorate (ph.d). his academic training fostered a deep understanding of cellular biology, molecular pharmacology, and translational research, setting the stage for his later work in drug discovery and disease modeling. with a growing interest in combining biological systems with advanced simulation tools, he also developed an appreciation for cross-disciplinary areas such as power electronics, where data integration and control systems play crucial roles.

💼 Professional endeavors

Dr. Khanna boasts more than 18 years of industrial research experience, working with prestigious organizations such as syngene international, piramal life sciences (plsl), strand life sciences, and yashraj biotechnology limited. currently, he serves as the head of integrated drug discovery & development at yashraj biotechnology limited, where he leads high-performing teams in the development of cutting-edge in vitro models. previously, he held leadership roles including senior director at intonation research laboratories and group lead at syngene international, overseeing complex biological projects and assay development.

🔬 Contributions and research focus

Dr. Khanna has significantly advanced the field of drug discovery, especially in the areas of cancer, neurodegenerative, cardiovascular, and inflammatory disorders. his work includes the iPSC - Stem cells development and validation of human-relevant disease models using stem cells (including ipsc), crispr-engineered cells, and advanced 2d/3d co-culture systems. he has also contributed to the standardization of biochemical and cell-based assays and led target engagement studies involving cetsa, protac, and nanobret technologies. through a data-driven and milestone-gated approach, he ensures regulatory compliance and research excellence. his analytical and scientific strategy often parallels principles found in power electronics, such as feedback control and system optimization.

🌍 Impact and influence

Dr. Khanna's leadership has enabled transformative research outcomes that align with industry benchmarks and regulatory standards. by fostering collaborations with cross-functional teams and outsourcing partners, he has significantly influenced the trajectory of drug discovery programs in india. his work has directly contributed to the identification and optimization of clinical iPSC - Stem cells candidates like the jak kinase inhibitor for pruritus. he has also led the development of 21 cfr part 11–compliant data strategies, shaping robust data governance within the discovery biology landscape. as integrated technologies continue to gain traction in biomedical research, his emphasis on data alignment mirrors the precision required in power electronics control frameworks.

📚 Academic cites

Dr. Khanna’s scientific contributions have been cited in multiple high-impact research studies, particularly in translational biology and pharmacological modeling. his publications, iPSC - Stem cells collaborations, and presentations at industry forums reflect his dedication to innovation and scientific communication. while specific citation metrics are not listed here, his impact is evident in the successful delivery of numerous discovery-phase projects and the clinical progression of lead compounds.

🧬 Legacy and future contributions

With a commitment to scientific rigor and innovation, dr. khanna continues to push the boundaries of drug discovery and translational research. his strategic vision includes expanding into organ-on-chip models, personalized therapy development, and high-throughput screening platforms. as technology and biology converge, his interdisciplinary mindset positions him to integrate fields like power electronics into next-generation biomedical solutions. his long-term legacy will be defined by the nurturing of scientific talent, enhancement of disease model accuracy, and promotion of global research collaborations.

Notable  Publications 

Title: Generation of human-induced pluripotent stem cell line from PBMC of healthy donor using integration-free Sendai virus technology
Author(s): Jaganmay Sarkar, Shreya Dhepe, Amrita Shivalkar, Rutuja Kuhikar, Shruti More, Vijay Bhaskar Reddy Konala, Paresh Bhanushali, Amit Khanna
Journal: Stem Cell Research

Dr. WenQing Yang – Translational preclinical modelling for cancer and autoimmune diseases – Industry Leadership Excellence Award

Dr. WenQing Yang - Translational preclinical modelling for cancer and autoimmune diseases - Industry Leadership Excellence Award

ClinBridge Biotechnology Corporation Limited - China

Professional Profile

SCOPUS

ORCID

🎓 EARLY ACADEMIC PURSUITS

WenQing Yang, Ph.D., embarked on a distinguished academic journey that laid the foundation for his influential career in biomedical research. His early education was marked by a profound interest in understanding complex biological systems, which guided him through rigorous academic training. Dr. Yang’s academic pursuits provided him with a robust understanding of animal disease modeling and cancer pharmacology, paving the way for his future contributions in these fields.

💼 PROFESSIONAL ENDEAVORS

With over 30 years of experience, Dr. Yang has made significant strides in drug discovery and development. His professional career began with a focus on early-stage drug discovery, where he demonstrated exceptional skill in advancing drug candidates from discovery to clinical development. Dr. Yang's career spans roles in both large pharmaceutical companies and small biotech firms, showcasing his versatility and leadership. His tenure as Founder and Chief Scientific Officer at Clinbridge Biotech Co. Ltd has been pivotal in establishing the company’s research and discovery infrastructure, driving scientific programs, and fostering global collaborations.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS

Dr. Yang’s research has been instrumental in the areas of cancer pharmacology, immuno-oncology, and autoimmune diseases. His work encompasses a wide range of activities, from animal disease modeling and cancer immunotherapy discovery to novel therapeutic targets validation. Dr. Yang’s expertise in dissecting the tumor micro-environment and validating biomarkers has led to significant advancements in understanding and treating complex diseases. His contributions to translational research have been crucial in bridging the gap between Translational preclinical modelling for cancer and autoimmune diseases preclinical studies and clinical applications.

🏆 ACCOLADES AND RECOGNITION

Throughout his career, Dr. Yang has been recognized for his exceptional contributions to biomedical research and drug discovery. His leadership in advancing over 20 drug candidates to PCC nomination or IND filing, with 15 molecules progressing to clinical trials, highlights his impact on the field. His role in leading translational sciences at Simcere Pharma Group Ltd further solidified his reputation as a leader in drug development and Translational preclinical modelling for cancer and autoimmune diseases translational research.

🌍 IMPACT AND INFLUENCE

Dr. Yang’s influence extends globally, with his research impacting both academic and clinical settings. His efforts in advancing drug discovery and development have led to innovative therapeutic approaches in oncology and immuno-oncology. By establishing and leading scientific programs Translational preclinical modelling for cancer and autoimmune diseases at Clinbridge Biotech and Simcere Pharma, Dr. Yang has played a crucial role in shaping the future of drug discovery and translational medicine, driving forward new treatments and therapeutic strategies.

🏛️ LEGACY AND FUTURE CONTRIBUTIONS

Dr. Yang’s legacy is characterized by his dedication to advancing biomedical research and drug discovery. His work has set new standards in cancer pharmacology, immuno-oncology, and autoimmune diseases. Looking ahead, Dr. Yang is poised to continue his impactful work, focusing on novel therapeutics and innovative research approaches. His commitment to scientific excellence and leadership will undoubtedly inspire future advancements in the field, ensuring that his contributions continue to benefit the biomedical community for years to come.

NOTABLE PUBLICATIONS